نتائج البحث - Baek‐Yeol Ryoo

تنقيح النتائج
  1. 1
    Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors

    Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors حسب Changhoon Yoo, Min‐Hee Ryu, Jungmin Jo, Inkeun Park, Baek‐Yeol Ryoo, Yoon‐Koo Kang

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis

    Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker an... حسب Changhoon Yoo, Min‐Hee Ryu, Young-Soon Na, Baek‐Yeol Ryoo, Chae-Won Lee, Yoon‐Koo Kang

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients

    Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients حسب Bum Jun Kim, Changhoon Yoo, Kyu‐pyo Kim, Jaewon Hyung, Seongjoon Park, Baek‐Yeol Ryoo, Heung-Moon Chang

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen

    Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen حسب Changhoon Yoo, Bum Jun Kim, Kyu‐pyo Kim, Jae‐Lyun Lee, Tae Won Kim, Baek‐Yeol Ryoo, Heung-Moon Chang

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    p53 Enhances Gefitinib-Induced Growth Inhibition and Apoptosis by Regulation of Fas in Non–Small Cell Lung Cancer

    p53 Enhances Gefitinib-Induced Growth Inhibition and Apoptosis by Regulation of Fas in Non–Small Cell Lung Cancer حسب Jin Kyung Rho, Yun Jung Choi, Baek‐Yeol Ryoo, Im II Na, Sung Hyun Yang, Cheol Hyeon Kim, Jae Cheol Lee

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan

    Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospec... حسب Jaekyung Cheon, Shigeo Shimose, Hyung‐Don Kim, Takashi Niizeki, Min‐Hee Ryu, Tomotake Shirono, Baek‐Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion

    Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion حسب Sang Min Yoon, Baek‐Yeol Ryoo, So Jung Lee, Jong Hoon Kim, Ji Hoon Shin, Jihyun An, Han Chu Lee, Young‐Suk Lim

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma

    Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma حسب Changhoon Yoo, JiHoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung Ah Lee, Kyung-Hun Lee, Tae‐You Kim, Baek‐Yeol Ryoo

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

    Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma حسب J. Lee, Cheolwon Suh, Hye Jin Kang, Baek‐Yeol Ryoo, Jooryung Huh, Young Hyeh Ko, Hyeon‐Seok Eom, Kihyun Kım, K. Park, W. S. Kim

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors

    Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors حسب Joo Young Kim, Jisup Kim, Yong-il Kim, Dong‐Hoon Yang, Changhoon Yoo, In Ja Park, Baek‐Yeol Ryoo, Jin‐Sook Ryu, Seung‐Mo Hong

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

    Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC) حسب Michael J. Pishvaian, M.S. Lee, Baek‐Yeol Ryoo, Stacey Stein, Ki Hoon Lee, Wendy Verret, Jessica Spahn, Hui Shao, B. Liu, Kunio Iizuka, Chih‐Hung Hsu

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma

    Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma حسب Changhoon Yoo, Joong‐Won Park, Yoon Jun Kim, Do Young Kim, Su Jong Yu, Tae Seop Lim, Su Jin Lee, Baek‐Yeol Ryoo, Ho Yeong Lim

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study

    Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study حسب Fabio Piscaglia, Kenji Ikeda, Ann‐Lii Cheng, Masatoshi Kudo, Masafumi Ikeda, В. В. Бредер, Baek‐Yeol Ryoo, Kalgi Mody, Min Ren, Zahra Ramji, Max W. Sung

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study

    Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study حسب Dong‐Hoe Koo, Sung‐Cheol Yun, Yong Sang Hong, Min‐Hee Ryu, Jae‐Lyun Lee, Heung-Moon Chang, Baek‐Yeol Ryoo, Yoon‐Koo Kang, Tae Won Kim

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis

    Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis حسب Jaekyung Cheon, Hong Jae Chon, Yeonghak Bang, Neung Hwa Park, Jung Woo Shin, Kang Mo Kim, Han Chu Lee, Joo‐Ho Lee, Changhoon Yoo, Baek‐Yeol Ryoo

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

    Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) حسب Seyoung Seo, Min‐Hee Ryu, Young Soo Park, Ji Yong Ahn, Yangsoon Park, Sook Ryun Park, Baek‐Yeol Ryoo, Gin Hyug Lee, Hwoon-Young Jung, Yoon‐Koo Kang

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

    Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, pha... حسب Yoon‐Koo Kang, Min‐Hee Ryu, Changhoon Yoo, Baek‐Yeol Ryoo, Hyun Jin Kim, Jong Jin Lee, Byung‐Ho Nam, Nikhil H. Ramaiya, Jyothi P. Jagannathan, George D. Demetri

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

    The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors حسب Jin Kyung Rho, Yun Jung Choi, Jin Kyung Lee, Baek‐Yeol Ryoo, Im Il Na, Sung Hyun Yang, Seung‐Sook Lee, Cheol Hyeon Kim, Young Yoo, Jae Cheol Lee

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients

    Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients حسب Seung Hee Seo, Sung-Eun Kim, Yoon‐Koo Kang, Baek‐Yeol Ryoo, Min‐Hee Ryu, Jae Ho Jeong, Shin Sook Kang, Mihi Yang, Jung Eun Lee, Mi‐Kyung Sung

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

    Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC) حسب Matthew Man Pok Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P. Hack, Jessica Spahn, B. Liu, Hesham Abdullah, Ruth He, Ki Hoon Lee

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: